FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126641566> ?p ?o ?g. }

• W3126641566 endingPage "105192" @default.
• W3126641566 startingPage "105192" @default.
• W3126641566 abstract "This study examined whether palbociclib and cetuximab prolonged overall survival (OS) versus placebo and cetuximab. In this double-blind, randomized, phase 2 trial (PALATINUS), patients with platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent/metastatic head and neck squamous-cell carcinoma received cetuximab and either palbociclib (arm A) or placebo (arm B). The primary endpoint was OS; 120 patients were required to have ≥80% power to detect a hazard ratio (HR) of 0.6 (median OS of 10 months in arm A and 6 months in arm B) using a one-sided, log-rank test (P = 0.10). 125 patients were randomized (arm A: 65, arm B: 60). Median follow-up was 15.9 months (IQR, 11.3–22.7). Median OS was 9.7 months in arm A and 7.8 months in arm B (HR, 0.82; 95% CI, 0.54–1.25; P = 0.18). Median progression-free survival was 3.9 months in arm A and 4.6 months in arm B (HR, 1.00; 95% CI, 0.67–1.5; P = 0.50). The most common treatment-related adverse events in arm A were rash (39 patients, 60.9%) and neutropenia (26, 40.6%; three febrile) and in arm B was rash (32, 53.3%). There was no significant difference in median OS with palbociclib and cetuximab versus placebo and cetuximab. Pfizer Inc (NCT02499120)." @default.
• W3126641566 created "2021-02-15" @default.
• W3126641566 creator A5003404406 @default.
• W3126641566 creator A5004940655 @default.
• W3126641566 creator A5005956102 @default.
• W3126641566 creator A5007561793 @default.
• W3126641566 creator A5009523282 @default.
• W3126641566 creator A5011675274 @default.
• W3126641566 creator A5017427697 @default.
• W3126641566 creator A5019281726 @default.
• W3126641566 creator A5026198438 @default.
• W3126641566 creator A5027112485 @default.
• W3126641566 creator A5028104092 @default.
• W3126641566 creator A5031584884 @default.
• W3126641566 creator A5040858214 @default.
• W3126641566 creator A5057038406 @default.
• W3126641566 creator A5061224094 @default.
• W3126641566 creator A5064319129 @default.
• W3126641566 creator A5072430373 @default.
• W3126641566 creator A5075134210 @default.
• W3126641566 date "2021-04-01" @default.
• W3126641566 modified "2023-10-04" @default.
• W3126641566 title "Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial" @default.
• W3126641566 cites W1986241711 @default.
• W3126641566 cites W1998040747 @default.
• W3126641566 cites W2000436105 @default.
• W3126641566 cites W2063721051 @default.
• W3126641566 cites W2108836663 @default.
• W3126641566 cites W2112845420 @default.
• W3126641566 cites W2114986305 @default.
• W3126641566 cites W2136158663 @default.
• W3126641566 cites W2136871952 @default.
• W3126641566 cites W2161482321 @default.
• W3126641566 cites W2167571044 @default.
• W3126641566 cites W2311671592 @default.
• W3126641566 cites W2397565476 @default.
• W3126641566 cites W2507803635 @default.
• W3126641566 cites W2529484692 @default.
• W3126641566 cites W2613669325 @default.
• W3126641566 cites W2769632596 @default.
• W3126641566 cites W2903493423 @default.
• W3126641566 cites W2950591923 @default.
• W3126641566 cites W2963353895 @default.
• W3126641566 cites W2986633517 @default.
• W3126641566 doi "https://doi.org/10.1016/j.oraloncology.2021.105192" @default.
• W3126641566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33571736" @default.
• W3126641566 hasPublicationYear "2021" @default.
• W3126641566 type Work @default.
• W3126641566 sameAs 3126641566 @default.
• W3126641566 citedByCount "19" @default.
• W3126641566 countsByYear W31266415662021 @default.
• W3126641566 countsByYear W31266415662022 @default.
• W3126641566 countsByYear W31266415662023 @default.
• W3126641566 crossrefType "journal-article" @default.
• W3126641566 hasAuthorship W3126641566A5003404406 @default.
• W3126641566 hasAuthorship W3126641566A5004940655 @default.
• W3126641566 hasAuthorship W3126641566A5005956102 @default.
• W3126641566 hasAuthorship W3126641566A5007561793 @default.
• W3126641566 hasAuthorship W3126641566A5009523282 @default.
• W3126641566 hasAuthorship W3126641566A5011675274 @default.
• W3126641566 hasAuthorship W3126641566A5017427697 @default.
• W3126641566 hasAuthorship W3126641566A5019281726 @default.
• W3126641566 hasAuthorship W3126641566A5026198438 @default.
• W3126641566 hasAuthorship W3126641566A5027112485 @default.
• W3126641566 hasAuthorship W3126641566A5028104092 @default.
• W3126641566 hasAuthorship W3126641566A5031584884 @default.
• W3126641566 hasAuthorship W3126641566A5040858214 @default.
• W3126641566 hasAuthorship W3126641566A5057038406 @default.
• W3126641566 hasAuthorship W3126641566A5061224094 @default.
• W3126641566 hasAuthorship W3126641566A5064319129 @default.
• W3126641566 hasAuthorship W3126641566A5072430373 @default.
• W3126641566 hasAuthorship W3126641566A5075134210 @default.
• W3126641566 hasConcept C121608353 @default.
• W3126641566 hasConcept C126322002 @default.
• W3126641566 hasConcept C141071460 @default.
• W3126641566 hasConcept C142724271 @default.
• W3126641566 hasConcept C143998085 @default.
• W3126641566 hasConcept C168563851 @default.
• W3126641566 hasConcept C203092338 @default.
• W3126641566 hasConcept C204787440 @default.
• W3126641566 hasConcept C207103383 @default.
• W3126641566 hasConcept C27081682 @default.
• W3126641566 hasConcept C2776694085 @default.
• W3126641566 hasConcept C2777063308 @default.
• W3126641566 hasConcept C2778570526 @default.
• W3126641566 hasConcept C2779998722 @default.
• W3126641566 hasConcept C44249647 @default.
• W3126641566 hasConcept C526805850 @default.
• W3126641566 hasConcept C71924100 @default.
• W3126641566 hasConcept C90924648 @default.
• W3126641566 hasConceptScore W3126641566C121608353 @default.
• W3126641566 hasConceptScore W3126641566C126322002 @default.
• W3126641566 hasConceptScore W3126641566C141071460 @default.
• W3126641566 hasConceptScore W3126641566C142724271 @default.
• W3126641566 hasConceptScore W3126641566C143998085 @default.
• W3126641566 hasConceptScore W3126641566C168563851 @default.
• W3126641566 hasConceptScore W3126641566C203092338 @default.
• W3126641566 hasConceptScore W3126641566C204787440 @default.

• next